ストックスクリーナーアプリを入手
1.86
0.54%
0.01
アフターアワーズ：
1.86
前日終値:
$1.85
開ける：
$1.85
24時間の取引高:
2.49M
Relative Volume:
1.46
時価総額：
$391.14M
収益：
$194.75M
当期純損益:
$-51.26M
株価収益率:
-3.5769
EPS:
-0.52
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
+8.77%
1か月 パフォーマンス:
+39.85%
6か月 パフォーマンス:
+35.77%
1年 パフォーマンス:
+96.85%
1日の値動き範囲:
$1.78
$1.86
1週間の範囲:
$1.63
$1.86
52週間の値動き範囲:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-31 | ダウングレード | Needham | Buy → Hold |
| 2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 繰り返されました | Needham | Buy |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-02 | 開始されました | JP Morgan | Overweight |
| 2019-03-20 | 開始されました | Citigroup | Neutral |
| 2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 繰り返されました | Needham | Buy |
| 2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-12-19 | 開始されました | Piper Jaffray | Overweight |
| 2017-12-07 | 開始されました | BTIG Research | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | Needham | Buy |
| 2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-15 | 開始されました | Aegis Capital | Buy |
| 2016-09-29 | 開始されました | Brean Capital | Buy |
| 2016-03-16 | 繰り返されました | Needham | Buy |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN
Akebia Therapeutics to present at upcoming investor conferences - MSN
Akebia Therapeutics (AKBA) Set to Announce Earnings on Thursday - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard
Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Akebia stock climbs 8% on dialysis provider supply agreement - MSN
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St
Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia
Akebia Therapeutics secures dialysis drug contract - Investing.com
Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne
Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com
Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK
Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan
A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News
Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada
Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - Lelezard
Akebia Therapeutics Inc. [AKBA] Records 200-Day SMA of $1.3806 - Knox Daily
Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges - GuruFocus.com
Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
A stock that deserves closer examination: Akebia Therapeutics Inc. (AKBA) - US Post News
Ratio Revelations: Akebia Therapeutics Inc. (AKBA)’s Financial Metrics in the Spotlight - The Dwinnex
Akebia shares gain momentum as analyst highlights Vafseo's market potential in dialysis centers - Investing.com
Akebia Therapeutics (NASDAQ:AKBA) Given "Buy" Rating at HC Wainwright - MarketBeat
Examining the Potential Price Growth of Akebia Therapeutics Inc. (AKBA) - Knox Daily
Akebia, U.S. Renal Care sign dialysis treatment supply deal - Investing.com
Akebia, U.S. Renal Care sign dialysis treatment supply deal By Investing.com - Investing.com UK
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Marketscreener.com
Akebia Therapeutics Inc. (AKBA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
SVP, Chief Legal Officer Hadas Nicole R. sale 12,016 shares of Akebia Therapeutics Inc. [AKBA] - Knox Daily
Akebia Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2022 to Discuss Your RightsAKBA - Newsfile
Chartwell Partners Recruits CFO for Akebia Therapeutics - Hunt Scanlon Media
Alerce Investment Management L.P. Sells 7,457,213 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Ratios in Focus: Analyzing Akebia Therapeutics Inc. (AKBA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
0.88%
0.42%
大文字化:
|
ボリューム (24 時間):